Abbott Labs Sr. VP sold $5.72m in shares-July 24
Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows:
-
nutrition products (33.1%): pediatric nutrition products, nutritional supplements, and dietetic products;
-
diagnostic systems and instruments (23.1%);
-
medicine (18.5%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.;
-
vascular devices (13.9%): endoprosthetic systems, dilation catheters, arterial closures, etc.;
-
other (11.4%).
Net sales are distributed geographically as follows: the United States (31.1%), China (8.3%), India (5.3%), Germany (5%), Japan (4.4%),
the Netherlands (4%), Switzerland (3.7%), Russia (2.6%), Canada (2%), the United Kingdom (1.8%), and other (31.8%).
https://www.marketscreener.com/ABBOTT-LABORATORIES-11506/company/
https://www.finviz.com/insidertrading.ashx?oc=1204554&tc=2&b=2
Devices for Diabetes Patients Spur Growth at Medical Firms
Diabetes patients are increasingly using electronic skin patches and their phones, instead of pricking their fingers, to do the complex job of managing a disease that affects more than 30 million Americans.
The transformation in blood-sugar testing suggests how harnessing technology and data may drive improvements for disease management – and profits for manufacturers.
Many patients now wear coin-sized skin patches on their arms or abdomens that test for blood-sugar levels automatically, then send the data to a patient's smartphone or even to a wearable insulin pump that delivers the medicine.
Patients in the U.S. using the devices, known as continuous-glucose monitors, numbered almost 840,000 as of March 31, more than double the 389,000 using them at the end of 2017, according to Seagrove Partners LLC, a health-care research and consulting firm.
Sales of the products are fueling growth at companies including DexCom Inc., Abbott Laboratories and Medtronic PLC.
Their sales of the devices are expected to hit $3.2 billion this year, triple the 2016 total, according to JPMorgan Chase.
The market for the devices "is extremely large and growing really fast," said Mike Hill, who heads the Medtronic unit selling the sensors.
Tracking blood-sugar levels is vital for many diabetics, who must regularly check if they are within healthy levels or need to take insulin, sugar or some other medicine to avoid fainting or worse.
For years, many patients have had to prick their fingers several times a day to draw blood and then insert the blood into a meter for a reading.
Use of digital blood-sugar monitors, which first hit the market in the mid-2000s, has soared in recent years partly because the devices have become more accurate and more health plans are paying for them.
https://www.marketscreener.com/DEXCOM-INC-9115/news/Devices-for-Diabetes-Patients-Spur-Growth-at-Medical-Firms-28974237/